Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea.
Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
J Gastrointest Surg. 2018 May;22(5):771-777. doi: 10.1007/s11605-018-3681-5. Epub 2018 Jan 26.
We assessed whether intraoperative nefopam would reduce opioid consumption and relieve postoperative pain in patients undergoing laparoscopic gastrectomy.
The 60 enrolled patients were randomly assigned to the control (n = 32) or nefopam (n = 28) group. All patients were blinded to their group assignment. We administered 100 ml of normal saline only (control group) or 20 mg of nefopam mixed in 100 ml normal saline (nefopam group) after anesthesia induction and at the end of surgery. The cumulative amount of fentanyl via intravenous patient-controlled analgesia (PCA), incidence of rescue analgesic medication, and numerical rating scale (NRS) for postoperative pain were evaluated along with the total remifentanil consumption.
The mean infusion rate of remifentanil was significantly lower in the nefopam group (0.08 ± 0.05 μg/kg/min) than in the control group (0.13 ± 0.06 μg/kg/min) (P < 0.001). Patients in the nefopam group required less fentanyl via intravenous PCA than those in the control group during the first 6 h after surgery (323.8 ± 119.3 μg vs. 421.2 ± 151.6 μg, P = 0.009). Additionally, fewer patients in the nefopam group than in the control group received a rescue analgesic during the initial 6 h postoperatively (78.6 vs. 96.9%, P = 0.028). The NRS measured while patients were in the post-anesthetic care unit was significantly lower in the nefopam group than in the control group (3.8 ± 1.1 vs. 4.8 ± 1.4, P = 0.012). The subsequent NRS obtained after patients had been transferred to the general ward was comparable between the two groups during the following postoperative period.
Intraoperative nefopam decreased postoperative pain and opioid consumption in the acute postoperative period after laparoscopic gastrectomy. Hence, nefopam may be considered as a component of multimodal analgesia after laparoscopic gastrectomy.
我们评估了术中使用奈福泮是否会减少腹腔镜胃切除术后患者的阿片类药物消耗并缓解术后疼痛。
60 名入组患者被随机分配到对照组(n=32)或奈福泮组(n=28)。所有患者均对其分组情况不知情。麻醉诱导后和手术结束时,我们仅给予 100ml 生理盐水(对照组)或 20mg 奈福泮混合在 100ml 生理盐水中(奈福泮组)。通过静脉患者自控镇痛(PCA)评估累积芬太尼用量、解救镇痛药物的发生率以及术后疼痛的数字评分量表(NRS),同时评估总瑞芬太尼消耗量。
奈福泮组(0.08±0.05μg/kg/min)瑞芬太尼输注率明显低于对照组(0.13±0.06μg/kg/min)(P<0.001)。与对照组相比,奈福泮组患者在术后 6 小时内通过静脉 PCA 需要的芬太尼更少(323.8±119.3μg 比 421.2±151.6μg,P=0.009)。此外,奈福泮组在术后最初 6 小时内接受解救镇痛的患者少于对照组(78.6%比 96.9%,P=0.028)。奈福泮组患者在麻醉后护理单元时的 NRS 明显低于对照组(3.8±1.1 比 4.8±1.4,P=0.012)。在随后的术后期间,两组患者转移到普通病房后获得的后续 NRS 相似。
术中使用奈福泮可减少腹腔镜胃切除术后急性术后期间的术后疼痛和阿片类药物消耗。因此,奈福泮可被视为腹腔镜胃切除术后多模式镇痛的一部分。